Esther12
Senior Member
- Messages
- 13,774
Wow... this is genuinely the worst thing I've seen in ages. So bad it could be helpful?
23. Wessely S, C.T., Hirsch S, Pawlikowska T, Wallace P, Wright DJ. Postinfectious fatigue: prospective cohort study in primary care. Lancet., 1995. 345(8961): p. 1333-8.
LOL at that reference for that claim.
24. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2016 Feb 7;2:CD003200.
So Cochrane being used to discredit a patient organisation while they fail to correct their errors.
As we saw above, reviewer seems oblivious to the problems with current measures for CFS, and sees no benefit in developing a valid one. Seems there's a concern that accurate info could be harmful to CFS patients - not sure that concern should be affecting funding decisions for research.
the association between infection and development of CFS disappears when fatigue and psychological morbidity are adjusted for. 23
23. Wessely S, C.T., Hirsch S, Pawlikowska T, Wallace P, Wright DJ. Postinfectious fatigue: prospective cohort study in primary care. Lancet., 1995. 345(8961): p. 1333-8.
LOL at that reference for that claim.
The applicants advise that “the ME/FM Action Network is one of our primary partners.” A review of this organization’s site (http://www.mefmaction.com/) reveals a focus on conceptualizing CFS as a physical disease best managed by rest and activity limitation.
Regarding the evidence for optimal treatment of CFS, a 2016 Cochrane review has concluded: 23 “Patients with CFS may generally benefit and feel less fatigued following exercise therapy, and no evidence suggests that exercise therapy may worsen outcomes. A positive effect with respect to sleep, physical function and self-perceived general health has been observed”.24
24. Larun L, Brurberg KG, Odgaard-Jensen J, Price JR. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2016 Feb 7;2:CD003200.
So Cochrane being used to discredit a patient organisation while they fail to correct their errors.
It is not clear why validating the Hexoskin (i.e. confirming that it is measuring what it says it measures) is important to the management of CFS patients, and I would be cautious of providing real-time feedback of all these measures to a population that is defined by unhelpful vigilance to physical symptoms and somatic attribution.
As we saw above, reviewer seems oblivious to the problems with current measures for CFS, and sees no benefit in developing a valid one. Seems there's a concern that accurate info could be harmful to CFS patients - not sure that concern should be affecting funding decisions for research.